CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...
Phase 3
Peoria, Arizona, United States and 335 other locations
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...
Phase 3
Phoenix, Arizona, United States and 141 other locations
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma...
Phase 2
Peoria, Arizona, United States and 73 other locations
PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, ...
Phase 2
Chandler, Arizona, United States of America and 124 other locations
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed repl....
Phase 3
Phoenix, Arizona, United States and 127 other locations
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated w...
Phase 3
Sun City, Arizona, United States and 148 other locations
treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...
Phase 3
Phoenix, Arizona, United States and 75 other locations
levels compared with placebo in participants with moderate-to-severe asthma.Study participation will last approximately 65 weeks, including ...
Phase 2
Tempe, Arizona, United States and 120 other locations
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compa...
Phase 3
Paradise Valley, Arizona, United States and 41 other locations
safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma...
Phase 2
Scottsdale, Arizona, United States of America and 161 other locations
Clinical trials
Research sites
Resources
Legal